Roland Loudenburg, M'P'H' ABD Mountain Plains Evaluation, LLC Salem, SD

1
Roland Loudenburg, M.P.H. ABDMountain Plains
Evaluation, LLCSalem, SD
Summary of SDWP IMT Program Interim Evaluation
Findings
2
Example of Program Design and Evaluation
Assessments
Phase I Time Varies
Phase II 90 days
Phase III 90 days (Approximately)
Phase IV 180 days (Approximately)
Detox/ Withdrawal Cognitive- Stabilization
Intensive SA Treatment (comparable to inpatient)
½way House
Outpatient SA Treatment
Intake Assessment Battery
Begin Phase II Assessment Battery
End Phase II Assessment Battery
End Phase III Assessment Battery
End Phase IV Assessment Battery
3
Overlapping the IMT Treatment Model with Stages
of Recovery for Stimulant Users
Phase I Time Varies
Phase II 30-90 days
Phase III 90 days
Phase IV 180 days
DAY 0
DAY 15
DAY 45
DAY 120
DAY 180
Phase II
Phase III
Phase IV
Adjustment
Honeymoon
The Wall
Withdrawal
Resolution
Assessments
4
Evaluation Assessments

• Data is collected at Intake and completion of
  Phase II, III, and IV
• Areas assessed in addition to substance use
  include
• Mental Health (CESD)
• Family Functioning (Family APGAR)
• Social Support (ISEL)
• Self-Efficacy/Readiness for Change (MASE/URICA)
• Other data
• Track UAs, Adverse Events, and Program Status

5
Depression Symptoms

• Overall, participants in the program report a
  reduction in depression symptoms through out the
  program as measured by the CES-D.

CES-D Scores Range form o to 60, a score of 16 or
above indicates possible depressive symptoms
6
(No Transcript)
7
Family Functioning Scale Scores

• Program participants report on average an
  increase in family functioning during the course
  of the program.

FAPGAR Scores Range form 0 to 10, a score of 4
or less indicates concerns in family functioning
8
(No Transcript)
9
Readiness to Change

• Overall, program participants are progressing
  along the Stages of Change continuum as they
  progress through the program.

10
Temptation and Confidence

• Program participants report a reduction in
  temptation to use and an increase in their
  confidence to not use methamphetamine as they
  move through the program.

11
(No Transcript)
12
(No Transcript)
13
(No Transcript)
14
(No Transcript)
15
Status of All Program Participants
Note There is a approximately one month in lag
time before adverse events, violations, or
completions are recorded in the database.
16
Status of Group Participants Scheduled to
Complete as of begging of October 2008
17
Survival Analysis for Groups Scheduled to have
Completed the Program
18

• The following slides provide an illustration of
  program participation of four randomly selected
  program groups progression through the program.
• o passed UA
• x indeterminate UA
• - Failed UA
• V Adverse Event
• p - Projected date of transition from phase
• C Completed
• D Dropped
• 2, 3, 4 Received testing/assessment forms for
  corresponding phase
• X exit interview

19
(No Transcript)
20
(No Transcript)
21
(No Transcript)
22
(No Transcript)
23
National Research Benchmarks

• From Matrix Model Outpatient Study of 420
  individuals
• 67.1 of the sample remaining in treatment longer
  than 2 weeks
• 56 remained in treatment longer than 1 month
• Average length of treatment stay averaged 7.87
  (/- 6.6 weeks)
• Retention as indicated by a treatment stay of 90
  days or longer was 35

Source Addiction, April 2007
24
National Research Benchmarks (cont)

• Mean number of meth-free urine samples collected
  was 4.79 (/- 5.86)
• The percentage of participants who provided three
  consecutive (in weeks) drug-free urine samples
  during the course of treatment was 45
• 16-week treatment regimen (i.e. treatment
  completers) was 33.3

Source Addiction, April 2007
25
Comparison to National Benchmarks

• National Benchmark

• SDWP IMT Data

• Average length of treatment stay averaged 7.87
  (/- 6.6 weeks)
• Retention as indicated by a treatment stay of 90
  days or longer was 35
• Mean number of meth-free urine samples collected
  was 4.79 (/- 5.86)

• The average length of treatment recorded for
  participants completing Phase III is 12 weeks
• Approximately 70 remain active in program or
  have completed the program
• UA data available for analysis for Phase III and
  IV combined provided an average number of 40.3
  drug free urine samples per client.

26
Contact InformationRoland Loudenburg, M.P.H.
ABDMountain Plains Evaluation, LLCP.O. Box 530
/ 201 N. Main St.Salem, SD 57058RolandL_at_MtPlain
s.Com or rbl_at_triotel.net
26